Table 3.
Cost-effectiveness of COBRA-BPS from the health systems perspective
| Bangladesh (100% coverage) | Pakistan (60% coverage) | Sri Lanka (100% coverage) | |
|---|---|---|---|
| Total incremental cost for cost-effectiveness analysis (US$)* | $1 421 174 180 | $766 327 830 | $377 973 350 |
| Mean incremental reduction of systolic blood pressure (mm Hg)10 | 4·39 (7·84–0·94) | 4·99 (9·63–0·35) | 6·22 (8·98–3·45) |
| Cardiovascular disease DALYs borne by eligible population (n)† | 4 285 514 | 3 082 505 | 676 600 |
| Avertable cardiovascular disease DALYs (n)‡ | 413 895 | 338 397 | 92 586 |
| Incremental cost per cardiovascular disease DALY averted (US$) | $3430 | $2270 | $4080 |
| WHO threshold for being cost-effective (US$)§ | $5090 | $4450 | $12 310 |
| Gross domestic product per capita17 | $1560 | $1460 | $4080 |
Data are n, mm Hg (95% CI), or 2020 US$. Monetary values are rounded to the nearest $10. DALY=disability-adjusted life-year.
*
A breakdown of the cost types can be found in the appendix (p 8).
†
Individuals aged 40 years or older with hypertension in rural communities.
‡
Based on an estimated 2·2% reduction in cardiovascular disease DALYs per 1 mm Hg reduction in systolic blood pressure.